Tumor-targeting drug-loaded particles

Details Tumor-targeting drug-loaded particles Tumor-targeting drug-loaded particles

A - Human Necessities

61

K

A61K 31/337 (2006.01) A61K 31/335 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2520475

A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carrier. An apoptosis-inducing agent in a pharmaceutically acceptable carrier may be administered before or concomitantly therewith. Nanoparticles or microparticles (e.g., cross-linked gelatin) of the therapeutic agent (e.g., paclitaxel) also may be used. The nanoparticles or microparticles may be coated with a bioadhesive coating. Microspheres that agglomerate to block the entrance of the lymphatic ducts of the bladder to retard clearance of the microparticles through the lymphatic system also may be employed. This invention also uses drug-loaded gelatin and poly(lactide-co-glycolide) (PLGA) nanoparticles and microparticles to target drug delivery to tumors in the peritoneal cavity, bladder tissues, and kidneys. Fig. 1 (left) shows multiple tumors disseminated through the peritoneal cavity of a mouse implanted with intraperitoneal human Hs766T pancreatic xenograft tumors under room light and (right) under UV light.

L'invention concerne une composition destinée à administrer un agent thérapeutique antitumoral à un patient. Ladite composition contient une préparation à libération rapide d'un agent induisant l'apoptose des cellules tumorales, une préparation à libération lente d'un agent thérapeutique antitumoral et un excipient pharmaceutiquement acceptable. Un agent induisant l'apoptose contenu dans un excipient pharmaceutiquement acceptable peut être administré avant ladite composition ou simultanément. Des nanoparticules ou des microparticules (de gélatine réticulée, par exemple) d'agent thérapeutique (du paclitaxel, par exemple) peuvent également être utilisées. Lesdites nanoparticules ou microparticules peuvent comporter un revêtement bioadhésif. Des microsphères s'agglomérant pour bloquer l'entrée des canaux lymphatiques de la vessie de sorte à retarder la clearance des microparticules à travers le système lymphatique peuvent encore être utilisées. L'invention met également en oeuvre une gélatine à charge médicamenteuse et des nanoparticules et des microparticules de poly(lactide-co-glycolide) (PLGA) pour cibler la libération de médicament sur des tumeurs de la cavité péritonéale, des tissus de la vessie et des reins.

Affiliated with

Also associated with

Rating

Tumor-targeting drug-loaded particles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor-targeting drug-loaded particles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor-targeting drug-loaded particles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1439025